Processa Pharmaceuticals, Inc.

corporate_fare Company Profile

Processa Pharmaceuticals, Inc.

PCSA·NASDAQ·Life Sciences·CIK 0001533743

Processa Pharmaceuticals, Inc. is a publicly listed clinical-stage biopharmaceutical company incorporated in Delaware on March 29, 2011. The company focuses on developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. Their strategy involves identifying existing cancer therapies with well-understood mechanisms of action that are cornerstones of current treatment regimens but are highly toxic with treatment-limiting side effects. Processa then devises technologies to alter how the body metabolizes or distributes these therapies to enhance their therapeutic effect and reduce toxicity. The company develops its NGC therapies using its proprietary Regulatory Science Approach. Currently, one NGC small molecule is in a Phase 2 trial, while another is in pre-clinical development.

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 10 items for PCSA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-14, rated 8/10. Across its 10 most recent items scored 7 or higher, the top rating is 10/10, with 7 rated 8 or above. Recent SEC coverage for PCSA spans 10-Q, 8-K, DEF 14A, 10-K/A.

Recent high-impact activity:

Processa 10-Q Details Vidya Merger Terms, Elion Settlement, and $200M PIPE Ownership Split (2026-08-14)
Processa Acquires Vidya Therapeutics with $200M PIPE to Advance BTK Inhibitor (2026-07-29)
Processa Acquires Vidya Therapeutics in Reverse Merger, Raises $200M PIPE to Advance BTK Inhibitor (2026-07-29)
Shareholders to Vote on 200,000 Share Increase for Incentive Plan Amidst Going Concern (2026-06-18)
Processa Pharmaceuticals Issues Going Concern Warning Amidst Significant Cash Burn and Urgent Capital Needs (2026-05-07)

Financial Snapshot

Fiscal year ended December 31, 2025

Net Income

-$13.56M

Diluted EPS

-$10.36

Op. Cash Flow

-$11.39M

Operating Income

-$13.99M

Cash & Equivalents

$5.54M

Debt / Equity

0.00×

Shares Outstanding

2.57M sh

Source: 10-K · filed 2026-04-30 · accession 0001493152-26-020731

Browse all tickers starting with P →

show_chartPrice Chart

Loading chart...

feed PCSA - Latest Insights

Filing Type

Date Range

PCSA

Aug 14, 2026, 4:06 PM EDT

Filing Type: 10-Q

Importance Score:

Processa 10-Q Details Vidya Merger Terms, Elion Settlement, and $200M PIPE Ownership Split

Price at Filing: $2.43

Real-time Price: $1.88

Change: -$0.550 (-23%)

Market Cap: $5.168M

Sentiment: Negative

View Wiseek Article

PCSA

Jul 29, 2026, 7:57 AM EDT

Source: Reuters

Importance Score:

Processa Acquires Vidya Therapeutics with $200M PIPE to Advance BTK Inhibitor

Price at Filing: $2.27

Real-time Price: $1.88

Change: -$0.3901 (-17%)

Market Cap: $5.168M

Sentiment: Positive

View Wiseek Article

PCSA

Jul 29, 2026, 7:35 AM EDT

Filing Type: 8-K

Importance Score:

Processa Acquires Vidya Therapeutics in Reverse Merger, Raises $200M PIPE to Advance BTK Inhibitor

Price at Filing: $2.59

Real-time Price: $1.88

Change: -$0.7099 (-27%)

Market Cap: $5.168M

Sentiment: Positive

View Wiseek Article

PCSA

Jun 18, 2026, 4:05 PM EDT

Filing Type: DEF 14A

Importance Score:

Shareholders to Vote on 200,000 Share Increase for Incentive Plan Amidst Going Concern

Price at Filing: $2.12

Real-time Price: $1.88

Change: -$0.240 (-11%)

Market Cap: $5.168M

Sentiment: Negative

View Wiseek Article

PCSA

May 07, 2026, 4:18 PM EDT

Filing Type: 10-Q

Importance Score:

Processa Pharmaceuticals Issues Going Concern Warning Amidst Significant Cash Burn and Urgent Capital Needs

Price at Filing: $2.87

Real-time Price: $1.88

Change: -$0.990 (-34%)

Market Cap: $5.168M

Sentiment: Negative

View Wiseek Article

PCSA

Apr 30, 2026, 5:14 PM EDT

Filing Type: 10-K/A

Importance Score:

Processa Pharmaceuticals Amends 10-K to Detail $1.4M Capital Raises and Executive Compensation

Price at Filing: $2.70

Real-time Price: $1.88

Change: -$0.820 (-30%)

Market Cap: $5.168M

Sentiment: Neutral

View Wiseek Article

PCSA

Apr 30, 2026, 5:11 PM EDT

Filing Type: 8-K

Importance Score:

Chief Development Officer Transitions to Part-Time Role, No Longer Executive Officer

Price at Filing: $2.70

Real-time Price: $1.88

Change: -$0.820 (-30%)

Market Cap: $5.168M

Sentiment: Neutral

View Wiseek Article

PCSA

Feb 23, 2026, 11:00 AM EST

Filing Type: SCHEDULE 13D/A

Importance Score:

Major Investor Increases Stake in Processa Pharmaceuticals with $200K Purchase

Price at Filing: $2.09

Real-time Price: $1.88

Change: -$0.2067 (-10%)

Market Cap: $5.168M

Sentiment: Positive

View Wiseek Article

PCSA

Feb 19, 2026, 4:05 PM EST

Filing Type: 8-K

Importance Score:

Processa Pharmaceuticals' PCS12852 Licensing Agreement with Intact Therapeutics Terminates

Price at Filing: $2.28

Real-time Price: $1.88

Change: -$0.400 (-18%)

Market Cap: $5.168M

Sentiment: Negative

View Wiseek Article

PCSA

Jan 07, 2026, 8:30 AM EST

Filing Type: 8-K

Importance Score:

Processa Pharmaceuticals Regains Nasdaq Compliance, Averting Delisting Threat

Price at Filing: $3.58

Real-time Price: $1.88

Change: -$1.70 (-48%)

Market Cap: $5.168M

Sentiment: Positive

View Wiseek Article

Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets

corporate_fare Company Profile